湖北亨迪药业股份有限公司2025年半年度报告摘要

Group 1 - The company has approved a profit distribution plan, distributing 0 cash dividends and 0 bonus shares per 10 shares, while increasing capital reserves by 4.5 shares per 10 shares to all shareholders [2] - There has been no retrospective adjustment or restatement of previous accounting data [2] - The company has not experienced any changes in its controlling shareholder during the reporting period [3] Group 2 - The actual controller of the company has not changed during the reporting period [4] - There are no preferred shareholders or related holdings reported during the period [4] - There are no outstanding bonds as of the date of the semi-annual report approval [4]